Biologic agent activity in chronic lymphocytic leukemia: A framework for future therapies

Chadi Nabhan; Neil Dalal; Jayesh Mehta; Neil E. Kay

doi:10.3109/10428194.2010.545461

Biologic agent activity in chronic lymphocytic leukemia: A framework for future therapies

Chadi Nabhan, Neil Dalal, Jayesh Mehta, Neil E. Kay

Hematology

Research output: Contribution to journal › Review article

1 Scopus citations

Abstract

The previous decade has witnessed remarkable advances in our understanding and treatment of chronic lymphocytic leukemia. Chemoimmunotherapy has provided patients with unprecedented remission rates and has improved survival compared to chemotherapy alone. However, the availability of targeted therapies and monoclonal antibodies argues for exploring non-cytotoxic and biologic regimens for this disease. In this article, we review available targeted and non-chemotherapeutic agents for CLL, attempting to position these therapies in the treatment paradigm of CLL in the era of risk stratification as we move forward.

Original language	English (US)
Pages (from-to)	374-386
Number of pages	13
Journal	Leukemia and Lymphoma
Volume	52
Issue number	3
DOIs	https://doi.org/10.3109/10428194.2010.545461
State	Published - Mar 1 2011

Fingerprint

Keywords

Immunotherapeutic approaches
chemotherapeutic approaches
lymphoid leukemia
pharmacotherapeutics
signaling therapies

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Cite this

Nabhan, C., Dalal, N., Mehta, J., & Kay, N. E. (2011). Biologic agent activity in chronic lymphocytic leukemia: A framework for future therapies. Leukemia and Lymphoma, 52(3), 374-386. https://doi.org/10.3109/10428194.2010.545461

@article{72f98dbd748c49e4ba84c3eb6120bdec,

title = "Biologic agent activity in chronic lymphocytic leukemia: A framework for future therapies",

abstract = "The previous decade has witnessed remarkable advances in our understanding and treatment of chronic lymphocytic leukemia. Chemoimmunotherapy has provided patients with unprecedented remission rates and has improved survival compared to chemotherapy alone. However, the availability of targeted therapies and monoclonal antibodies argues for exploring non-cytotoxic and biologic regimens for this disease. In this article, we review available targeted and non-chemotherapeutic agents for CLL, attempting to position these therapies in the treatment paradigm of CLL in the era of risk stratification as we move forward.",

keywords = "Immunotherapeutic approaches, chemotherapeutic approaches, lymphoid leukemia, pharmacotherapeutics, signaling therapies",

author = "Chadi Nabhan and Neil Dalal and Jayesh Mehta and Kay, {Neil E.}",

year = "2011",

month = mar

day = "1",

doi = "10.3109/10428194.2010.545461",

language = "English (US)",

volume = "52",

pages = "374--386",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Biologic agent activity in chronic lymphocytic leukemia

T2 - A framework for future therapies

AU - Nabhan, Chadi

AU - Dalal, Neil

AU - Mehta, Jayesh

AU - Kay, Neil E.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - The previous decade has witnessed remarkable advances in our understanding and treatment of chronic lymphocytic leukemia. Chemoimmunotherapy has provided patients with unprecedented remission rates and has improved survival compared to chemotherapy alone. However, the availability of targeted therapies and monoclonal antibodies argues for exploring non-cytotoxic and biologic regimens for this disease. In this article, we review available targeted and non-chemotherapeutic agents for CLL, attempting to position these therapies in the treatment paradigm of CLL in the era of risk stratification as we move forward.

AB - The previous decade has witnessed remarkable advances in our understanding and treatment of chronic lymphocytic leukemia. Chemoimmunotherapy has provided patients with unprecedented remission rates and has improved survival compared to chemotherapy alone. However, the availability of targeted therapies and monoclonal antibodies argues for exploring non-cytotoxic and biologic regimens for this disease. In this article, we review available targeted and non-chemotherapeutic agents for CLL, attempting to position these therapies in the treatment paradigm of CLL in the era of risk stratification as we move forward.

KW - Immunotherapeutic approaches

KW - chemotherapeutic approaches

KW - lymphoid leukemia

KW - pharmacotherapeutics

KW - signaling therapies

UR - http://www.scopus.com/inward/record.url?scp=79951705088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951705088&partnerID=8YFLogxK

U2 - 10.3109/10428194.2010.545461

DO - 10.3109/10428194.2010.545461

M3 - Review article

C2 - 21323519

AN - SCOPUS:79951705088

VL - 52

SP - 374

EP - 386

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3

ER -

Access to Document

10.3109/10428194.2010.545461